FDA device-related FY 1999 appropriations
This article was originally published in The Gray Sheet
Report adopted 25-19 by the House Appropriations Committee June 16 sets FY 1999 funding for salaries and expenses at $148.5 mil., up 3.5% from $143.5 mil. in FY 1998. A companion measure adopted by the Senate Appropriations Committee on June 11 freezes spending at the current level. Overall, the House bill increases FDA funding for salaries and expenses in FY 1999 by 1.6%, from $857.5 mil. to $871.5 mil., not including user fees. The legislation pending in the Senate keeps appropriations at the FY 1998 level, exclusive of an $82.9 mil. provision for rental fees to the General Services Administration for FDA facilities ("The Gray Sheet" June 15, p. 30)
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.